Електронний репозитарій ДВНЗ "УжНУ": Search

Search

Results 11-20 of 57 (Search time: 0.001 seconds).

previous
1
2
3
4
5
...
6
next

Item hits:

Issue Date	Title	Author(s)
2016-10-20	Maintenance erlotinib versus erlotinib at disease progression inpatients with advanced non-small-cell lung cancer who have notprogressed following platinum-based chemotherapy (IUNO study)	Saulius Cicènas; Sarayut Lucien Geater; Petar Petrov; Yevgeniy Hotko; Gregory Hooper; Fan Xia; Nadejda Mudie; Yi-Long Wu
2014-02	Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status	Shikha Gaur; Linling Chen; Vincent Ann; Wei-Chen Lin; Yafan Wang; Vincent HS Chang; Yevgeniy Hotko; Her-Shuyong Shia; Nan Yong Hsu; Yun Yen
2013	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the PAVES Study	Tamás Pintera; Zandra Klippel; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Kurteva; Jan Novotny; Seamus O’Reilly; Tomas Salek; Maureen Reiner; Phuong Khanh Morrow; Mi Rim Choi; Sadie Whittaker; Charles Blanke
2014	HORMONOTHERAPY IN PATIENTS WITH BILATERAL BREAST CANCER	Y.S. Hotko; D.Y. Tsyhyka; S.V. Zhero; D.V. Prygara; N.Y. Pogorelova; O.I. Tsyhyka; V.Y. Ihnatko; O.T. Devinyak
2015	Final results from PAVES, a phase 3, randomized, double-blind, placebo-controlled trial of pegfilgrastim in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab for locally advanced or metastatic colorectal cancer (LA/mCRC) (NCT00911170)	T. Pinter; P.K. Morrow; A. Cesas; A. Croitoru; J. Decaestecker; P. Gibbs; Y. Hotko; J. Jassem; G. Kurteva; J. Novotny; S. O'Reilly; T. Salek; L. Khosrowshahi; M. Reiner; Z. Klippel; C. Blanke
2012	Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC)	Alberto F. Sobrero; Marc Peeters; Timothy Jay Price; Yevhen Hotko; Andres Cervantes-Ruiperez; Michel Ducreux; Thierry Andre; Emily Chan; Florian Lordick; Ying Tian; Roger Sidhu
2016	Peculiarities of breast cancer incidence rate in urban population and implementation of screening programs in health care system	Svyatoslav V Zhero; Yevhen S Hotko; Dmytro Y Tsyhyka; Victor Y Ihnatko; Natalia Y Pohorelova
2010-11-01	Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer	Готько, Євген Степанович; Peeters, Marc; Jay Price, Timothy
2013	MALE BREAST CANCER: CLINICAL PRESENTATION, DIAGNOSIS, TREATMEN	Готько, Євген Степанович
2013	Resultsof a phase III, randomized, double-blind, placebocontrolledtrialofpegfilgrastim (PEG) inpatients (pts) receivingfirst-line FOLFOX or FOLFIRI andbevacizumab (B) forcolorectalcancer (CRC)	Tamas Pinter; Esteban Abella; Alvydas Cesas; Adina Croitoru; Jochen Decaestecker; Peter Gibbs; Yevhen Hotko; Jacek Jassem; Galina Petrova Kurteva; Jan Novotny; Seamus O'Reilly; Tomas Salek; May F. Mo; L. MiRim Choiand Charles Davic Blanke